Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial | Trials | Full Text

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial | Trials | Full Text

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial

The emergence of new molecular targeted drugs provides new prospects for the treatment of advanced breast cancer; the future therapeutic trend includes chemotherapy combined ...

Authors:Shuo Wu, Liang Zhang, Huan Li, Junnan Xu, Cui Jiang and Tao Sun

Citation:Trials 2020 21:420

Content type:Study protocol

Published on: 24 May 2020

• ViewFull Text
 
• ViewPDF